BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31868681)

  • 1. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
    Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
    Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated α-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease.
    Lin CW; Lai TT; Chen SJ; Lin CH
    Geroscience; 2022 Jun; 44(3):1551-1562. PubMed ID: 35484471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease.
    Li CH; Chen TF; Peng PL; Lin CH
    J Neurol; 2022 Dec; 269(12):6530-6543. PubMed ID: 35965282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
    Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
    J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
    Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease.
    Lin YS; Lee WJ; Wang SJ; Fuh JL
    Sci Rep; 2018 Nov; 8(1):17368. PubMed ID: 30478269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.
    Liu HC; Lin WC; Chiu MJ; Lu CH; Lin CY; Yang SY
    PLoS One; 2020; 15(6):e0234519. PubMed ID: 32530970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
    Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
    J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control.
    Lin WC; Lu CH; Chiu PY; Yang SY
    Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
    J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and dementia with Lewy bodies.
    Frigerio I; Bouwman MMA; Noordermeer RTGMM; Podobnik E; Popovic M; Timmermans E; Rozemuller AJM; van de Berg WDJ; Jonkman LE
    Acta Neuropathol Commun; 2024 Jan; 12(1):4. PubMed ID: 38173031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid related cerebral microbleed and plasma Aβ40 are associated with cognitive decline in Parkinson's disease.
    Tsai HH; Tsai LK; Lo YL; Lin CH
    Sci Rep; 2021 Mar; 11(1):7115. PubMed ID: 33782518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.